The omission of breast radiotherapy after BCS for HER2-positive breast cancer is not recommended in any case, even when other conditions for the omission of irradiation are met (expected survival <10 years, pT1, pN0, R0, HR+) (Table 6). This evidence concerns the gene ERBB2 and breast carcinoma.